Pathstone Family Office’s Niagen Bioscience NAGE Stock Holding History

Pathstone Family Office’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,000	Closed	-$13K	–	347
2018 Q1	$13K	Buy	+3,000	New	+$15.7K	0.01%	206
2017 Q4	–	Sell	-3,000	Closed	-$13K	–	213
2017 Q3	$13K	Hold	3,000	–	–	0.01%	124
2017 Q2	$11K	Hold	3,000	–	–	﹤0.01%	312
2017 Q1	$8K	Buy	+3,000	New	+$8.51K	﹤0.01%	306
2016 Q4	–	Sell	-3,000	Closed	-$9K	–	210
2016 Q3	$9K	Hold	3,000	–	–	0.01%	136
2016 Q2	$12K	Buy	+3,000	New	+$14.2K	0.01%	127

Other funds holding NAGE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JMPWA

JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Pathstone Family Office's NAGE Position: Q2 2018 in Review

Pathstone Family Office sold out of Niagen Bioscience (NAGE) in Q2 2018, closing a stake of 3,000 shares — an estimated $13K sold.

Pathstone Family Office first reported a position in NAGE in Q2 2016 and held it in 6 quarters. The position peaked at $13K in Q1 2018. 64 funds tracked by Wall St. Rank hold NAGE as of Q2 2018.

Pathstone Family Office reported no remaining Niagen Bioscience position as of Q2 2018 after selling out during the quarter.
Pathstone Family Office sold 3,000 Niagen Bioscience shares in Q2 2018, an estimated $13K.
Pathstone Family Office first reported a position in Niagen Bioscience in Q2 2016 and held it in 6 quarters.
Pathstone Family Office's Niagen Bioscience position peaked at $13K in Q1 2018.
64 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2018.

Based on Pathstone Family Office's 13F filing for Q2 2018, filed 10 Aug 2018.